Article Text

Download PDFPDF

PR005/#410  Outcomes of neoadjuvant chemotherapy and radical hysterectomy for locally advanced cervical cancer at kigali university teaching hospital, Rwanda
Free
  1. Eugene Ngabonziza1,
  2. Rahel Ghebre2,
  3. Rebecca J Deboer3,
  4. Diomede Ntasumbumuyange1,
  5. Urania Magriples4,
  6. Jessica Marie George5,
  7. Surbhi Grover6 and
  8. Lisa Bazzett-Matabele7
  1. 1University of Rwanda, Obstetrics and Gynaecology, Kigali, Rwanda
  2. 2University of Minnesota, Obstetrics and Gynecology, Minneapolis, USA
  3. 3University of California San Francisco, Medical Oncology, San Francisco, USA
  4. 4Yale University, Obstetrics and Gynecology, New Haven, USA
  5. 5University of California Irvine, Information and Computer Science, Irvine, USA
  6. 6University of Pennsylvania, Radiation Oncology, Philadelphia, USA
  7. 7University of Botswana, Obstetrics and Gynaecology, Gaborone, Botswana

Abstract

Introduction To evaluate the clinical and surgical response of neoadjuvant(NACT) followed by radical hysterectomy, as well as recurrence rates and overall survival, in patients with locally advanced cervical cancer treated at Kigali University Teaching Hospital in Rwanda.

Methods Retrospective descriptive study: data collected from eligible patients FIGO stage IB2-IIA2, some exceptional stage IIB. Patients treated with neoadjuvant carboplatin/paclitaxel chemotherapy every 3 weeks for 3–4 cycles before radical hysterectomy. Clinical response, recurrence and survival rates were determined.

Results Between May 2016 and October 2018, 57 patients underwent NACT and 43(75.4%) were candidates for radical hysterectomy after clinical assessment. Median age was 56 years. 39(90.7%) patients received 3 cycles of NACT, 4(9.3%) received 4 cycles. Only 14% were HIV positive. FIGO stages were IB2 (32.6%), IIA1(27.9%), IIA2(30.2%) and IIB(9.3%). Mean tumor size before and after NACT was 5.9 cm and 2.07 cm, respectively. Thirty-eight(88.4%) patients underwent radical hysterectomy as planned. 5(11.6%) had surgery aborted due to metastatic disease, four(10.5%) had microscopic metastasis on final pathology. These nine(20.9%) patients were referred for adjuvant chemoradiation. Five(13.1%) patients showed no residual disease on final pathology. Mean time for follow up was 34.4 months. 32/41(78%) patients showed no evidence of recurrence, 8/41(19.5%) had documented recurrence and 2/43(4.7%) were lost to follow up. One and 2-year overall survival rates were 95.1% and 87%, respectively.

Conclusion/Implications Neoadjuvant chemotherapy with radical hysterectomy is a feasible treatment option for locally advanced cervical cancer in limited resource settings. It can be an alternative treatment option in countries without radiation facilities if gynecologists skilled at radical surgery are available.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.